TICKERNERD
Menu
ALDXALDXHealthcare · Biotechnology

ALDX Stock Forecast: Aldeyra Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$0.92
−21.05% on the day

The 6 Wall Street analysts covering Aldeyra Therapeutics, Inc. hold a median 12-month price target of $5 — +441.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 5 Oct 2026 — in the lower half.

Market cap
$70.6M
Ticker Nerd rank
40 / 100
Median analyst target
$5.00
Analysts covering
6
Revenue$0.0
Operating income−$5.9M
Net income−$5.5M
Free cash flow−$4.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.4%
1M
−37.6%
YTD
−82.2%
1Y
−83.9%
From 52W high
−83.7%
From 52W low
0.0%
$0.92
$5.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aldeyra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
92
Growth
84
Size
81
Quality
48
Accruals
39
Value
35
Revisions
28
Volatility
13
Momentum
7

Issuance (92): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26ALDXHigh $13.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $2.00Median $5.00High $13.00

The green dot is the last close — the median target sits +441.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Sept 2026HC Wainwright & Co.ReiteratesNeutral$2.00
29 Sept 2026BTIGReiteratesBuy$9.00
18 Mar 2026HC Wainwright & Co.DowngradeNeutral$10 → $2.00
18 Mar 2026HC Wainwright & Co.DowngradeNeutral—
10 Nov 2025BTIGReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
7 Apr 2025BTIGMaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
9 Aug 2024HC Wainwright & Co.ReiteratesBuy—
2 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024OppenheimerReiteratesOutperform—
3 Apr 2024OppenheimerUpgradeOutperform—
2 Apr 2024HC Wainwright & Co.ReinstatesBuy$10
17 Oct 2023CitigroupMaintainsBuy—
17 Oct 2023OppenheimerDowngradePerform—
9 Aug 2023OppenheimerReiteratesOutperform—
30 June 2023HC Wainwright & Co.ReiteratesBuy—
22 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Aldeyra Therapeutics, Inc. returned −83.9% against +17.0% for the S&P 500, dividends included.

ALDX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ALDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Aldeyra Therapeutics, Inc. (ALDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
−1.1×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−49.5%

Higher than 22% of US stocks

Return on assets
−22.7%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aldeyra Therapeutics, Inc. (ALDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aldeyra Therapeutics, Inc. has a market value of $70.6M and an enterprise value of $25.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$23.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$22.0M.

  • Shares outstanding: 60.3M.

  • Trailing P/E: −2.1×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aldeyra Therapeutics, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

ALDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALDXAldeyra Therapeutics, Inc.$70.6M
40
IMAImageneBio, Inc.$55.5M
26
CELUCelularity, Inc.$55.5M
30
CNTBConnect Biopharma Holdings Ltd.$56.5M
38
BOLDBoundless Bio, Inc.$58.3M
81
EDSAEdesa Biotech, Inc.$52.8M
47
HYPDHyperion DeFi, Inc.$59.0M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aldeyra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALDX news & analysis

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

Benzinga · 29 Sept 2026positive

Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request regarding its reproxalap program, a move that has pushed its shares higher on Tuesday as investors responded to the company's pushback against the prior FDA rejection.

Why it matters — A Aldeyra watcher would care because the dispute resolution request represents the company's next step in challenging the FDA's decision on reproxalap, which is central to its pipeline.

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

Seeking Alpha · 29 Sept 2026neutral

Aldeyra Therapeutics discussed the FDA review process for reproxalap, a treatment for dry eye disease, in a Seeking Alpha transcript. The discussion focused on FDRR and the regulatory pathway for the candidate.

Why it matters — An ALDX watcher would care because reproxalap's FDA review status is a key regulatory milestone for the company's pipeline.

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

MarketBeat · 29 Sept 2026negative

Aldeyra Therapeutics announced plans to submit a formal dispute resolution request to the FDA's Office of New Drugs, seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.

Why it matters — The FDA rejection and Aldeyra's appeal indicate a setback in the approval pathway for reproxalap, a key product candidate for the company.

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

Business Wire · 29 Sept 2026neutral

Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request to the FDA regarding reproxalap, its investigational candidate for treating dry eye disease. The request is expected to be reviewed by the FDA's Office of New Drug.

Why it matters — The dispute resolution process represents a regulatory step in reproxalap's path to approval, making the outcome significant for Aldeyra's dry eye disease development program.

Aldeyra Therapeutics to Host Regulatory Update Webcast

Business Wire · 28 Sept 2026neutral

Aldeyra Therapeutics announced it will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET, focusing on reproxalap, its investigational drug for dry eye disease. A live audio webcast and slide presentation will be accessible for the event.

Why it matters — ALDX watchers would care because the webcast will provide regulatory updates on reproxalap, a key candidate in the company's pipeline for treating dry eye disease.

FAQ

Frequently asked questions about ALDX stock

What is the ALDX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Aldeyra Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALDX stock a buy right now?

Of the 6 analysts covering Aldeyra Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aldeyra Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALDX?

As at 5 Oct 2026, Aldeyra Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (92 of 100).

Will ALDX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +441.3% from the last close, and Ticker Nerd's factor model ranks Aldeyra Therapeutics, Inc. 40 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALDX stock forecast for 2030?

No analyst covering Aldeyra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $13 over the next 12 months.

How has ALDX stock performed over the past year?

Aldeyra Therapeutics, Inc. returned -83.9% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aldeyra Therapeutics, Inc. do?

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases.

What is the latest news on ALDX?

The most recent item we track (Benzinga, 29 Sept 2026): "Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally". Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request regarding its reproxalap program, a move that has pushed its shares higher on Tuesday as investors responded to the company's pushback against the prior FDA rejection.

Company

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its current pipeline centers on small-molecule and related drug candidates for ophthalmology and other inflammatory conditions, including reproxalap for dry eye disease and allergic conjunctivitis, ADX-2191 for selected retinal disorders, and ADX-629 for several immune-related indications. The company also advances preclinical reactive aldehyde species modulator programs aimed at addressing systemic and retinal diseases. Aldeyra Therapeutics emphasizes treatments designed to modulate inflammatory pathways and improve patient care across eye disease, allergy, and broader immune-mediated segments. Based in Lexington, Massachusetts, Aldeyra Therapeutics operates as a clinical-stage biopharmaceutical developer with a portfolio positioned across multiple therapeutic areas and specialty markets.

CEO Dr. Todd C. Brady M.D., Ph.D. · 6 employees · United States · https://www.aldeyra.com